Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Equity (2023 - 2025)

Silence Therapeutics' Return on Equity history spans 3 years, with the latest figure at 0.0% for Q4 2025.

  • On a quarterly basis, Return on Equity changed 0.0% to 0.0% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.0%, a 0.0% change, with the full-year FY2025 number at 0.0%, up 1.0% from a year prior.
  • Return on Equity hit 0.0% in Q4 2025 for Silence Therapeutics, up from 0.01% in the prior quarter.
  • Over the last five years, Return on Equity for SLN hit a ceiling of 0.0% in Q4 2025 and a floor of 0.03% in Q3 2023.
  • Historically, Return on Equity has averaged 0.01% across 3 years, with a median of 0.01% in 2024.
  • Biggest five-year swings in Return on Equity: rose 2bps in 2024 and later changed 0bps in 2025.
  • Tracing SLN's Return on Equity over 3 years: stood at 0.03% in 2023, then skyrocketed by 85bps to 0.0% in 2024, then surged by 104bps to 0.0% in 2025.
  • Business Quant data shows Return on Equity for SLN at 0.0% in Q4 2025, 0.01% in Q3 2025, and 0.01% in Q2 2025.